LIPOSOMES CONTAINING STEROID ESTERS

LIPOSOMES CONTENANT DES ESTERS DE STEROIDES

English Abstract

ABSTRACT
Pharmaceutical composition for administration primarily to the
respiratory tract when treating and controlling anti-inflammatory
conditions comprising liposomes in combination with a compound of
the formula
<IMG> I
wherein Q is
<IMG>

<IMG>
and R1 is a saturated or unsaturated, straight or branched alkyl group
with 11-l9 carbon atoms and R is H, -COCH3, -COC2H5, -CO(CH2)2CH3
or -CO(CH2)3CH3.
The invention also refers to the compounds of the formula I per se
processes for preparation of these compounds and to a method for the
treatment of inflammatory conditions.

Claims

21
CLAIMS
1. A pharmaceutical composition for administration primarily to the
respiratory tract comprising liposomes in combination with a compound
of the formula
<IMG>
I
wherein Q is
<IMG>

22
<IMG>
and R1 is a saturated or unsaturated, straight or branched alkyl group
with 11-19 carbon atoms and R is H, -COCH3, -COC2H5, -CO(CH2)2CH3
or -CO(CH2)3CH3.
2. A composition according to claim 1 wherein the compound of formula
I is
<IMG>
in the form of a stereoisomeric mixture or an epimer of the R or S
type regarding the orientation of the substituents on the carbon atom
at position 20.

-23-
3. A composition according to claim 1 which consists of a
lyophilized liposome preparation containing a compound of the formula
I as defined in claim 1 or 2.
4. A process for the preparation of a pharmaceutical compo-
sition according to claim 1 characterized in
a) dissolving a compound of the formula I defined in claim 1
and a lecithin in an organic solvent,
b) evaporating the solvent and thus obtaining the liposomes
directly in an aqueous atmosphere, or
c) after evaporation, dispersing the lipid layers in an
aqueous (with or without lactose) medium and
d) shaking or sonicating the obtained suspension or alterna-
tively
e) drying of the liposome suspension.
5. A compound of the formula
<IMG> I
wherein Q is
<IMG>
(I-a)

-24-
<IMG> (I-b)
<IMG>
(I-c)
<IMG> (I-d)

-25-
<IMG> (I-e)
<IMG> (I-f)
and R1 is a saturated or unsaturated straight or branched alkyl
group with 11-19 carbon atoms and R is H, -COCH3, -COC2H5, -CO(CH2)2
CH3 or -CO(CH2)3CH3
6. A compound according to claim 5 wherein the compound of
formula I is

-25a-
<IMG>
in the form of a stereoisomeric mixture or an epimer of the R or S
type regarding the orientation of the substituents on the carbon
atom at position 20.
7. A process for the preparation of a compound of the
formula
<IMG>
(I)
wherein Q and R1 have the meaning given in claim 5, characterized
by
a) reaction of a compound of the formula
Q-OH
wherein Q has the definition given in claim 5, with a compound of
the formula
R1-COOH
wherein R1 has the definition given in claim 5, to the formation of
a compound or formula I, or

- 26 -
b) reaction of a compound of the formula
Q-OH
wherein Q has the definition given in claim 5, with a compound
of the formula
R1CO-X
wherein R1 has the definition given in claim 5 and X is a halogen
atom or the group <IMG> wherein R2 has the same definition
as R1, to the formation of a compound of the formula I, or
c) reaction of a compound of the formula
Q-X1
wherein Q has the definition given in claim 5 and X1 is a leaving
group, with a compound of the formula
R1COO ? A ?
wherein R1 has the definition given in claim 5 and A ? is a
cation, to the formation of a compound of the formula I.
8. A process according to claim 7 characterized in that
a compound according to claim 6 is prepared.
9. A compound according to claim 5, wherein Q has the
formula (I-a).
10. A compound according to claim 5, wherein Q has the
formula (I-b).

- 27 -
11. A compound according to claim 5, wherein Q has the
formula (I-c).
12. A compound according to claim 5, wherein Q has the
formula (I-d).
13. A compound according to claim 5, wherein Q has the
formula (I-e).
14. A compound according to claim 5, wherein Q has the
formula (I-f).
15. A compound according to claim 9, wherein R1COO is derived
from a carboxylic acid selected from the group consisting of
lauric acid, myristic acid, palmitic acid, stearic acid, oleic
acid, linolic acid and linolenic acid.
16. A compound according to claim 10, 11 or 12, wherein
R1COO is derived from a carboxylic acid selected from the group
consisting of lauric acid, myristic acid, palmitic acid, stearic
acid, oleic acid, linolic acid and linolenic acid.
17. A compound according to claim 13 or 14, wherein R1COO
is derived from a carboxylic acid selected from the group
consisting of lauric acid, myristic acid, palmitic acid, stearic
acid, oleic acid, linolic acid and linolenic acid.

Description

D 757-1 ~L2 5~3~ 3 85-06-12
Liposomes containing steroid esters
_
DESCRIPTION
Field of the Invention
The present invention relates to anti-inflammatory and antiallergic
pharmaceutical compositions containing liposomes including
pharmacoloyically active steroid esters, the steroid esters per se,
processes for the preparation of the compositions and the esters and
to methods of the pharmacological use of the compositions.
The object of the invention is to provide an anti-inflammatory and
antiallergic pharmaceutical composition containing a liposome-
incorporated steroid ester for the local administration e.g. to the
respiratory tract and thus obtaining a prolongation of the local reten-
tion of the drug and to direct the drug to specific target cells.
Background Art
It is well-known that phospholipids, when suspended in an excess of
aqueous solution, spontaneously forms multilamellar vesicles. Liposomes
have been used as carriers for different kinds of pharmaceutically
active compounds in order to improve drug delivery and to minimize
side effects of the therapy. For this purpose steroid esters have
been combined with liposomes as well.
Biochem. J. (1976) 158, 473-476 describes the combination of hydro-
cortisone palmitate and octanoate with liposomes for use in treatment
of rheumatoid arthritis.
Agents and Actions, vol. 12, 3 (1982) describes hydrocortisone palmitate
liposomes and the anti-inflammatory effect thereof.

2 ~.25~
Dexamethasone-21-palmitate has been reported to be given as a fat
emulsion in the treatment of arthritis (EP 41772).
Synthesis and spectroscopic properties of dexamethasone-21-linoleate
and dexamethasone-21-linolelaidate are reported and discussed
(Arzneim.-Forsch. 26(1) 7 (1976).
International Journal of Pharmaceutics, 16 (1983), 305-318 describes
the interaction of cortisone esters with liposomes.
DE 2712030 discloses administration of liposomes containing certain
steroids directly into an enclosed cavity. Liposomes for inhalation
is otherwise only described in connection with compositions of
liposomes and sodium chromoglycate (EP 84898).
Disclosure of the Invention
Liposomes administered by a systemic route is mainly retained by the
liver, but also the spleen and the lung show a significant degree
of retention (Chem. Pharm. Bull. 30, (6), 2248-2251 (1982)). The useful-
ness of this form of administration is therefore limited when an anti-
inflammatory and antiallergic effect primarily in the respiratory
tract is intended.
According to the invention an anti-inflammatory and antiallergic pharma-
ceutical composition containing steroid ester liposomes for local
administration primarily to the respiratory tract is described.
The composition according to the invention provides for an improvement
of the therapeutic properties of the steroid ester by a prolongation
of the local retention in the airways and a direction of the drug
; to specific target cells.
More particular, the present invention is concerned with a pharma-
ceutical composition comprising liposomes containing novel esterified
glucocorticoids.

83~
The novel esterified glucocorticoids are characterized by the general
formula
Q-OC-R
wherei n Q i s
CH2-
C=O
HO ~/J~ _ O~C ~ CH2CH2CH3
0~
~CH2-
O = C
- O-R
~o~ ~ ~ CH3
'~J
Cl ~12-
, OR
HO ~J~ - - CH3
~/~
F
0~ ~
F
ICH2 -
O =C / C~13
HO ~_-- / \CH
~'~Y~
O ~`~J

33~t
lcH2-
O= C OR
HO~ ~ CH3
= ~
o
ICH2-
0 C _-OCOCH2CH3
HO ~ CH
//\~J -
15 ~ ~ J
Rl is a saturated or unsaturated, straight or branched alkyl group
with 11-19 carbon atoms and R is H,-COCH3, -COC2H5, -CO(CH2)2CH3 or
CO(CH2)3CH3.
The degree of inclosure of the steroid to the liposomes are enhanced
by the esterification of the steroids in the 21-position.
The steroid esters of the formula I are new and constitute a part
of the invention.
The preferred ester groups are moieties of
CllH23CH lauric acid
C13H27CH myristic acid
C15H31COOH palmitic acid
C17H35COOH stearic acid
C17H33COOH ol eic acid
C17H31C~I linolic acid
C17H29CH linolenic acid

5 ~ 3~
The preferred steroid ester has the formula
CH200C[cH2]l4cH3
C=O
HO_ ~ _ o ~ ^~CH2CH2CH3
~ budesonidepalmitate
All budesonide esters can be obtained in two diastereomeric forms
depending on the asymmetric carbon in position 20.
0
The steroid esters Q-O-C-Rlare prepared by one of the following alterna-
tive methods.
A. Reaction of a compound of the Formula
Q-OH
wherein Q has the definition given above, with a compound of the for-
mula
RlCOOH
wherein Rl has the definition given above.
The esterification of the 21-hydroxy compound may be effected in known
manner e.g. by reacting the parent 21-hydroxy steroid with an appro-
priate carboxylic acid, advantageously in the presence of trifluoro-
acetic anhydride and preferably in the presence of an acid catalyst
e.g. p-toluenesulphonic acid.

3~
The reaction is advantageously effected in an organic solvent such
as benzene or methylene chloride; the reaction being conveniently
effected at a temperature of 20-100C.
B. Reaction of a compound of the formula
Q-OH
wherein Q has the definition given above, with a compound of the for-
mula
RlCO-X
wherein Rl has the definition given above and X is a halogen atom,
such as chlorine, bromine, iodine and fluorine, or the group -O-CI-R2
wherein R has the same definition as R . O
The parent 21-hydroxy compound may be treated with the appropriate
carboxylic acid halide or anhydride, preferably in a solvent such
as halogenated hydrocarbone e.g. methylene chloride and advantageously
in the presence of a base such as triethylamine or pyridine, preferably
at a low temperature e.g. -5 to ~30C.
C. Reaction of a compound of the formula
Q-Xl
wherein Q has the definition given above and Xl is a leaving group,
with a compound of the formula
RlCOO~A~
wherein Rl has the definition given above and A~ is a cation.
A salt of the appropriate carboxylic acid, for example, an alkali
metal e.g. lithium, sodium or potassium salt or a triethylammonium
or tetrabutyl ammonium salt may be reacted with the appropriate
alkylating agent of the formula Q-Xl where Q is the same as

7 ~ 3~
above and Xl is a leaving group such as Cl, Br, I, mesylate or
p-toluenesulphonate, preferably in a polar solvent such as acetone,
methylethyl ketone or dimethyl formamide, conveniently at a temperature
in the range 25-100C.
Preparation oF the composition according to the invention
The lecithins used in this invention have fatty acid chains of diffe-
rent lengths and therefore have different phase-transition tempera-
tures. Examples of lecithins used are those derived from egg and
soybean and synthetic lecithins 11ke dimyristoyl phosphatidylcholine
(DMPC), dipalmitoyl phosphatidylcholine (DPPC) and distearoyl
phosphatidylcholine (DSPC). By manipulation of the structural lecithins
stable carriers with variable biodegradable properties could be
formulated. This would enable one to prolong the release of the
entrapped steroid ester.
The extent of the interaction of the steroid ester with e.g. dipalmi-
toylphosphatidylcholine (DPPC) vesicles is dependent on the ester
chain length with increased ir,teraction observed as the chain leng-
thens.
The inclusion of cholesterol or cholesterol derivatives in liposome
formulations has become very common due to its properties in increasing
liposome stability.
The initial stages of the preparation of liposomes according to the
present invention may conveniently follow procedures described in
the literature i.e. the components being dissolved in a solvent e.g.
ethanol or chloroform which is then evaporated. The resulting lipid
layer is then dispersed in the selected aqueous medium whereafter
the solution is either shaken or sonicated. The liposomes oF this
invention preferably have a diameter of between 0.1 and lOIum.
In addition to the main liposome-forming lipid(s) which is usually
phospholipid, other lipids (e.g. cholesterol or cholesterol stearate)
in the amount of 0-40% w/w of the total lipids may be included -to
modify the structure of the liposome membrane. In optimizing the uptake

of the liposome a third component providing a negative charge (e.g.
phosphatidic acid) or a positive charge (e.g. stearylamine acetate
or cetylpyridinium chloride) may be incorporated.
A wide range of proportions of steroid ester to lipid during formation
may be used depending on the lipid and the conditions used. Drying,
~reeze-drying or spray drying)of the liposomes in the presence of
lactose can be used with a lactose content in the range of O to 95 %
of the final composition.
The composition according to the invention which is particularly pre-
ferred contains liposomes and budesonide-21-palmitate. The routes
of administration involves powder aerosols, instillationg nebulization
and pressurized aerosols.

5~'æ5
Working Example~
Steroid esters
The invention is further illustrated by the following
examples to which it is not limited. All the mass spectra
have been obtained by chemical ionization mass spectro-
metry (CH4-gas) and they are all in agreement with the
molecular weights of the compounds. The purity of each
compound has been determined on a HPLC (High Performance
Liquid Chromatography) system using a ~Bondapak C18 column
(300 x 3.9 mm i.d.) with a flow rate of 1.0 ml/min and
with ethanol/H2O in ratio between 70:30 and 90;10 as the
mobile phase.
Example 1. Budesonide-21-palmitate (Method B?
Budesonide (1 mmole) was dissolved in pyridine (20 ml).
Palmitoyl chloride (2 mmole) was added at 0C and then at
ambient temperature overnight. While cooling ~he mixture
with ice 2M hydrochloric acid was added until acidic
reaction. The mixture was extracted with chloroform (3x50
ml). The organic phase was successively shaken with 5%
sodium bicarbonate and water, dried (Na2SO4) and evaporated.
The raw materlal was purified by preparative thin layer
chromatography (Silica gel; 3~ EtOH: 97~ CHC1~). Yield:
40%. Purity: 95.5%. MS-CI (CH4): MH = 669, M ~ 29 = 697.
Example 2. Budesonide-21-laura~e (Method B)
Reaction of budesonide (0.5 mmole) with lauryl chloride
(0.25 ml) in pyridine (3 ml) according to Example 1 gave
after preparative thin-layer chromatography (Silica gel;
3% EtOH: 97% CHC13) the title compound. Yield: 47~. MS-CI
(CH4): MH = 613, M + 29 = 641.
~ r~c/~ 11a r k

lo
3~
Example 3. Budesonid-21-myristate (Method B)
The myristoyl chloride was synthesized by refluxing
myristic acid (7.0 g) and thionyl chloride (9 ml) in
trichloroethylene (100 ml) for 3 hours. The solvent was
then evaporated.
Budesonide (2 mmole~ and myristoyl chloride ~2.4 mmole) in
methylene chloride (40 ml) was treated with triethylamine
(2.4 mmole) in methylene chloride (lO ml) for 2 hours at
room temperature. Methylene chloride was added and the
organic phase was successively treated with lM HCl and
water (3 x 100 ml). Chromatography (Sephadex LH20; chloro-
form) after drying (Na2SO4) and evaporation of the solvent
gave the title compound in 65% yield. Purity: 98.2%. MS-CI
(CH4): M~ = 641; M ~ 29 = 669.
Example 3b. Budesonide-21-myristate (Method C)
Budesonide-21-mesylate (0.5 mmole; prepared according to
CA 57, 13842d (1962)), myristic acid (0.5 mmole) and
triethylamine (0.5 mmole) in dimethylformamide (10 ml) was
stirred for 2 hours at 50C. The solvent was evaporated in
vacuo and using the same work-up procedure as in method B
gave after chromatography the title compound, identical
with the compound isolated in method B.
Example 3c. Budesonide-21-myristate (Method_A)
Budesonide (1 mmole), myristic acid (l mmole) and p-
toluenesulfonic acid (5 mg) were refluxed in benzene (30
ml) for 5 hollrs. The organic phase was successively shaken
with 5~ sodium bicarbonate and water, dried (Na2SO4) and
evaporated. Purification by preparative thin-layer chro-
matography gave the title compound, identical with the
compound isolated in method B.
~ f~c~c~ k

25~
Example_4. Bu eson_de-21-stearate (Method B)
Reaction of budesonide (1 mmole) with stearoyl chloride
(1.0 ml) in pyridine (6 ml) according to Example 1 gave
after preparative thin-layer chromatography (Silica gel;
3% EtOH: 97% C~C13) the title compound. Yield: 74%. MS-CI
(CH4): MH = 697; M + 29 = 725.
Example 5. Budesonide-21-oleate (Method B)
Reaction of budesonide (1.16 mmole) and oleoyl chloride
(1.4 mmole) in methylene chloride (50 ml) with triethyl-
amine (1.4 mmole) in methylene chloride (5 ml) 2 hours at
room temperature gave after work-up (example 3) and
chromatography (Silica gel; hexane-acetone (80:20)) the
title compound in 22% yield. Purity: 98.7%. MS-CI (CH4):
MH = 695; M + 29 = 723.
Example 6. Betamethasone-21-laurate (Method B3
Reaction of betamethasone (2 mmole) and lauryl chloride
(2.4 mmole) in dimethylformamide ~20 ml) with triethyl-
amine (2.4 mmole) in dimethylformamide (5 ml~ for 2 hours
at room temperature gave after evaporation of dimethyl-
formamide and work-up (example 3) and chromatography
(Silica gel; hexane-acetone (60:40)) the title compound in
22% yield. Purity: 92.7%. MS-CI (CH4): MH = 575; M + 29
= 603.
Example 7. Betamethasone-21-myristate (Method B)
Reaction of betamethasone (2 mmole) and myristoyl chloride
(2.4 mmole) in methylene chloride (40 ml) and dimethyl
formamide (5 ml) with triethylamine (2.4 mmole) in methylene
chloride (10 ml) for 2 hours at room temperature gave
after evaporation of dimethylformamide and work-up (example
3) and chromatography (Silica gel; hexane-acetone (70:30))
the title compound in 29% yield. Purity: 97%. MS-CI (CH~):
MH = 603; M ~ 29 = 631.

-
12
Reaction of betamethasone (0. 5 mmole) with palmitoyl
chloride (1.0 mmole) in pyridine (10 ml) according to
Example 1 gave after preparative thin-layer chromatography
(Silica gel 3%; EtOH: 97% CHC13) the title compound.
Yield: 33%. MS-CI (CH4): MH = 631; M + 29 = 659.
Example 9._Betamethasone-21-oleate (Method B3
Reaction of betamethasone ~2 mmole) and oleoyl chloride (3
mmole) in dimethylformamide (20 ml) with triethylamine (3
mmole) in dimethylformamide (5 ml) for 2 hours at room
temperature gave after evaporation of dimethylformamide
and work-up (example 3) and chromato~raphy (Sephadex LH20;
chloroform) the title compound. Purity: 96.7~. MS-CI
(CH4): MH = 657; M + 29 = 685.
Example 10. Betamethasone-21-laurate-17-val~ r~
B)
Reaction of betamethasone-17-valerate (2 mmole) and
lauroyl chloride (2. 4 mmole) in methylene chloride (90 ml)
with triethylamine l2.4 mmole) in methylene chloride ~10
ml) for 2 hours at room temperature gave after work-up
(example 3) and chromatography (Sephadex LH20; chloroform)
the title compound in 62~ yield. Purity: 97.8%. MS-CI
(CH4): MH = 659; M -~ 29 = 687.
Example ll._Betamethasone-21-myristate-17-valerate
Reaction of betamethasone-17-valerate (2 ~nole) and
myristoyl chloride (2. 4 mmole) in methylene chloride (90
ml) with triethylamine (2.4 ~nole) in methylene chloride
(10 ml) for 2 hours at room temperature ga~e after work-up
(example 3) and chromatography (Sephadex LH20; chloroform)
the title compound in 62% yield. Purity: 95.5%. MS-CI
(CH4): MH = 687; M + 29 = 715.

13
Example 12. Betamethasone-21-palmitate-17-valerate
Reaction of betamethasone-17-valerate (1 mmole) and
palmitoyl chloride ~1.2 mmole) in methylene ~hloride (50
ml) with triethylamine (1.2 mmole) in methylene chloride
(10 ml) for 2 hours at room temperature gave after work-up
(example 3) and chromatography (Sephadex LH20; chloroform~
the title compound in 63% yield. Purity: 95.9%. MS-CI
(CH4): MH = 715; M ~ 29 = 743.
Example 13. Betamethasone-21-stearate-17-valerate
(Method B)
Reaction of betamethasone-17-valerate (2 mmole) and
stearyl chloride (2.4 mmole) in methylene chloride (90 ml)
with triethylamine (2.4 mmole) in methylene chloride (10
ml) for 2 hours at room temperature gave after work-up
(example 3) and chromatography (Sephadex LH-20;
chloroform:heptane:ethanol (20:20:1)) the title compound
in 59~ yield. Purity: 92%. MS-CI (CH4~: MH = 743; M + 29
_ 771.
Example 14. Flumethasone-21-laurate (Method B)
Reaction of flumethasone (1.0 mmole) and lauroyl chloride
(1.5 mmole) in dimethylformamide (5 ml) and methylene
chloride (40 ml) with triethylamine (1.5 mmole) in methylene
chloride for 2 hours at room temperature gave after
evaporation of dimethylformamide and work-up (example 3)
and chromatography (Silica gel; hexane:acetone (70:30))
the title compound in 64% yield. Purity: 97.7%. MS-CI
(CH4): MH = 593; M + 29 = 621.
Example 15. Flumethasone-21-palmitate (Method B?
Reaction of flumethasone (0.5 mmole) with palmitoyl
chloride (loO mmole) in pyridine (10 ml) according to
Example 1 have after preparative thin-layer chromatography
(Silica gel; 3% EtOH: 97% CHC13) the title compound.
Yield: 38%. Purity: 98.5%. MS-CI (CH4): MH = 649; M + 29
= 677.

l4
Example 16. Flumethasone-21-stear _ _ _Method B)
Reaction of flumethasone ~1.0 mmole) and s~earoyl chloride
(1.5 mmole) in dimethylformamide (5 ml~ and methylene
chloride (40 ml) with triethylamine (1.5 mmole) in methyl-
ene chloride (lO ml) gave after evaporation of dimethyl-
formamide and work-up (example 3) and chromatography
(Silica gel; hexane:acetone (70:30)) the title compound in
38~ yield. Purity: 90%. MS-CI (CH4): MH = 677.
Example 17. Flumethasone-21-oleate (Method B)
Reaction of flumethaosne tl.0 mmole) and oleoyl chloride
(1.5 mmole) in dimethylformamide (5 ml) and methylene
chloride (40 ml) with triethylamine (1.5 mmole) in methyl-
ene chloride (10 ml) gave after evaporation of dimethyl-
formamide and work-up (example 3) and chromatography
(Silica gel; hexane:acetone 170:30)~ the title compound in
12% yield. Purity: 98.2%. MS-CI (CH4): MH = 675; M + 29
= 703.
Example 18. Flumethasone-21-laurate-17-propionate
(Method_B~
Reaction of flumethasone-17-propionate (l mmole) and
lauroyl chloride (1.5 mmole) in methylene chloride (40 ml)
with triethylamine (1.5 mmole) in methylene chloride (10
ml) gave after work-up (example 3) and chromatography
(Silica gel; hexane:acetone (70:30)) the title compound in
33~ yield. Purity: 94.4%. MS-CI (CH4): MH = 649; M + 29
= 677.
Exam~le l9. Flumethasone-21-myristate-l~p opionate
(Method B)
. ~
Reaction of flumethasone-17-propionate (1 mmole) and
myristoyl chloride (1.7 mmole) in methylene chloride (40
ml) with triethylamine (1.7 mmole) in me-thylene chloride
(10 ml) gave after work-up ~example 3) and chromatography
(Silica gel; hexane:acetone (70:30)) -the ti-tle compound in
55% yield. Purity: 96.7%. MS-CI (CH4): MH = 677.

~3L2~ 3~3
Exam~le 20. Flumethasone-21~palmitate-17~propionate
(Method B)
.
Reaction of flumethasone-17-propionate (2.8 mmole) and
palmitoyl chloride (3.3 mmole) in methylene chloride (150
ml) with triethylamine (3.3 mmole) in methylene chloride
(10 ml) gave after work-up (example 3) and chromatography
(Sephadex LH20; chloroform~ the title compound in 14~
yield. Purity: 98.8%. MS-CI (CH4): MH = 705; M + 29 =
733.
Example 21. Flumethasone-17~propionate-21-stearate
(Method B)
Reaction of flumethasone-17-propionate (1.0 mmole) and
stearoyl chloride (1.5 mmole) in methylene chloride (40
ml) with triethylamine (1.5 mmole) in methylene chloride
(10 ml) gave after work-up (example 3~ and chromatography
(Silica gel; hexane:acetone (70:30)) the title compound in
44% yield. Purity: 95%. MS-CI (CH4): MH = 733; M+ + 29 =
761.
Example 22. Flunisolide 21-laurate_(Method B)
Reaction of flunisolide (0.5 mmole) and lauroyl chloride
(0.64 mmole) in me-thylene chloride ~20 ml) with triethyl-
amine (0.64 mmole) in methylene chloride (5 ml~ gave after
work-up (example 3) and chromatography (Silica gel;
hexane:acetone (70:30)) the title compound in 65% yield.
Purity: 97.6%. MS-CI (CH4): MH = 612; M + 29 = 645.
Example_23. Flunisolide-21-myristate (Method_B)
Reaction of flunisolide (0.5 mmole) and myristoyl chloride
(0.65 mmole) in methylene chloride (20 ml) with triethyl-
amine (0.65 mmole) in methylene chloride (5 ml) gave after
work-up (example 3) and chromatography (Silica gel;
hexane:acetone (60:40)) the title compound in 54% yield.
Purity: 98.5%. MS-CI (CH4): MH = 645; M + 29 = 673.

16
~ 3
Example 24. Fluni olide-21-palmitate (Method B~
Reaction of flunisolide (433 mg), palmitoyl chloride ~400
mg) and triethylamine (500 mg~ in methylene chloride ~8
ml) for 2 hours at room temperature gave a~ter work-up
(example 3) and preparative thin-layer chromatography
(Silica gel; chloroform) the title compound in 29% yield.
Purity: 98.5~. MS-CI ~CH4): MH = 673; M + 29 = 701.
Example 25. Flunisolide-21-stearate (Method B)
Reaction of flunisolide (0.46 mmole) and stearoyl chloride
(0.7 mmole) in methylene chloride (40 ml) with
triethylamine (0.7 mmole) in methylene chloride (10 ml)
gave after work-up (example 3) and chromatography (Silica
gel; hexane:acetone (70:30)) the title compound in 53%
yield. Purity: 92~. MS-CI (CH4): MH = 701; M + 29 = 729.
Example 26. Beclomethasone-21~ _mitate-17-p~ate
(Method B)
.
Reaction of beclomethasone-17-propionate (40 mg),
palmitoyl chloride (100 mg) and triethylamine (50 mg) in
methylene chloride (5 ml~ for 2 hours at room temperature
gave after work-up (example 3) and preparative thin-layer
chromatography (Silica gel; 3% EtOH: 97% CHC13) the title
compound in 54~ yield. MS-CI (CH~): MH = 703.
Example 27. Dexamethasone-21~palmitate-17-propionate
(Me_ od B)
Reaction of dexamethasone-17-propionate (4 mmole) and
palmitoyl chloride (8 mmole) in methylene chloride (100
ml) with triethylamine (8 mmole) in methylene chloride (30
ml) for 2 hours at room temperature gave after work-up
(example 3) and chroma-tography (Sephadex LH20; heptane:
chloroform:ethanol (20:20:1)) the title compound in 25%
yield. Purity: 96%. MS CI (CH4~: MH = 687; M -~ 29 = 7150

Comeositions ~L 2~3~
Example 1. Preparation of a formulation for instillation
.. . .
Synthetic dipalmitoylphosphatidylcholine (45 mg), cholesterol (2.25 mg)
and budesonide-21-palmitate (4.5 mg) are mixed in a glass tube. All
components are dissolved in chloroform. Most o-f the solvent is evapo-
rated by the use of N2 and then under reduced pressure, which forms
a thin film of the lipid components on the surface of the glass tube.
An aqueous solution (0.9% NaCl) is added to the lipids. Formation
of the liposomes is performed at a temperature above the phase tran-
sition temperature of the lipids. The liposomes are Formed by shaking
or sonication of the solution with the probe of a sonicator. The result-
ing suspension contains liposomes ranging from very small vesicles
to 2 ,um in size.
Example 2. Preparation of a formulation for inhalation
The preparation of the liposomes is performed according to Example 1,
where the aqueous solution contains 10% lactose. The ratio between
lactose and lipid is 10:1. The liposome suspension is frozen on dry
ice and lyophllized. The dry product is micronized resulting in
particles with a mass mean aerodynamic diameter (MMAD) of about 2 ,um.
5iological Tests
. . . _ .
Anti-inflammator~ effect
Intratracheal instillation of Sephadex beads into rats leads to
bronchial and also to alveolar inflammation. This provokes interstitial
lung edema, which increases the lung weight, and the inflammation
can be graded as the increase of the lung weight compared to a saline-
instilled control group. The lung edema formation can be counteracted
by pretreatment wi-th glucocor-ticoids, preferably by local administration
as intra-tracheal instillation or as inhalation. Ideally an anti-
inflammatory action should be obtained only at the site of glucocorti-
coid application in -the lung, but no-t in the rest of the body as this
in long term treatment can lead to therapy limiting systemic side
effec-ts.
The differentiation between glucocorticoid actions in the treated
lung region and outside this area can be tested in the following way.

1~
~2~0~
Sprague Dawley rats (225 9) were slightly anaesthetized with ether
and the glucocorticoid test preparation (in liposomes suspended in
saline) in a volurne of 0.5 ml/kg was instilled into just the left
lung lobe. Two h later a suspension of Sephadex (5 mg/kg in a volume
of 1 mg/kg) was instilled in the trachea well above the bifurcation
so that the suspension reached both the left and right lung lobes.
Twenty h later the rats were killed and the left and right lung lobes
dissected out and weighed separately. Also the spleen weight and the
body weight gain over the 20 h were determined. Control groups got
vehicle instead of glucocorticoid preparation and saline instead of
Sephadex suspension to determine the weight of non-drug treated
Sephadex edema and the normal lung weight as well as the normal spleen
weight and body weight gain.
As stated above an ideal glucocorticoid preparation should have a
very high glucocorticoid activity at the site of application in lung,
but with low activity outside this area. Therefore, in the selected
model an optimal preparation should more or less completely block
the edema in the locally pretreated left lung lobe, but have much
less activity in the right lung half and no significant inhibitory
action on the spleen weight and the body weight gain. It has been
considered more important to search for a high degree of separation
between the local activity (exemplified with the left lung) to the
other activities than to search for a high absolute potency (high
activity per mg drug) for the action in the left lung. In the test
protocol used, doses were selected leading to a more or less complete
block of the edema in the left lung and at these dose levels the extent
of the other activities was estimated. At the selected dose 7-9 rats
were tested in parallel. Mean ~ s.e.m. was calculated and compared
with Student's t-test to the results of the corresponding Sephadex
control group.
The results of the comparative studies are given in Table 1. The
pharmacological profile of the new compounds was compared to that
of budesonide (selected as a conventional glucocorticoid having some

19
local activity as judged in skin tests) and to those of budesonide-21-
valerate, dexamethasone-21-palmitate, fluocinolone acetonide-21-
palmitate and hydrocortisone-21-palmitate (representing compounds
outside the scope of the invention). Budesonide, budesonide-21-valerate
and hydrocortisone-21-palmitate did not fulfil the requirement of
a very high local activity (only up to 38% reduction of edema in left
lung). Dexamethasone-21-palmitate and fluocinolone-21-palmitate
completely blocked the left lung edema, but this was coupled to as
high activity in the other lung half as well as to significant reduc-
tion of body weight gain and to spleen (Table 1). Thus, none of the
tested preparations falling outside the scope of the invention had
selective glucocorticoid activity for the site of application in lung.
The preparations of the new compounds of the invention had a much
more selective activity for the application site in lung. They all
more or less completely blocked the edema of the left lung (minimum
87% protection for beclomethasone-21-palmitate-17-propionate). This
was surprisingly coupled to only a low or moderate protective activity
in the other lung (maximally about 45% protection) and to no
statistically significant reduction of body weight gain or spleen.
Table 1.

~ ~ a~ 20
c a~ ~ _~ ~ _ _ _ _ _ _ _
~ o ~ V~ V~
., 5 YZZZZZ Z~1~ Z
~C~ ______ __~_
3 ~ C -- N ~ O O ~D ~D CO 00 CO
(~> O . ~ N N ~ O O "~
O 1~ 0 I I ~ I .- I I
a~
_ . . . ~
_ __ _ _ _ _
U~ U~ ~ ~ ~ V~
~ZZZZZ Z
c~c~ ~ 1~ 1~1
O
O
O O ~ ')~
.-- I~ Ln l~ J' O N C~
O s d- I ~ ~ ~ ~ ~) N O a~ I
~ .~
a
~ __~
O
~ a~ * ~ * *
~ O * * * ~ ~ # ~ ~
115 ., ~ r~ o~ o ~ ~3 ~ :) ~ ~,
E ~ co o o o o(`~> 1~ N N
1:~ ~ . ~ ~ ~ I
___ ~_
.,
a~ ~ Ln LS~
~,
,- OLn LO Ln ~ ~Lr~ O ~
v) O n ~) ~t~~> t~> ~ ~ (~ o t~)
c o E ~ ~ ~ ~ ~ ~ ~ ~ ~
., ~ ~
x
c~ .. ~ ~
L--
~: a~
~ ~ ~ ~
O~c ,, a~
o o ~o
~ L E
,~ r~
a , ,_
cl ~ ~a~ I ~ I
O I ~~> c I f~S N
~1 ~ ~aJ ~~ ~ 01 ~ I ~
C I E , ~, ., ~ ~ v) I a~ , a) E
, ~ E 0 E ~ ~ ~, ~ E
c I c~ ~5 ~ ~ ~ E ~ 5 c ~L c
.,, I a E ~ ~ ~ ~ a~ CL o I 0 ~
I ~ I ~ I ~ s E I ~ I ~ ~ ~ cn
al I N ~ 8 . I ~ 01 ~1$ ~ a l N .,
Sl I N ~ N ~ I (.)1 > N O I 4--
~1 a.\ I I I N ~ I I I 1~ al ., V~
I ~ al ,-- I:IJ I N O I N c a~ O I:J) >
o, v. O I O c a) ~1 1 o c u~ ., ~:
u~ ~ u~ S '' n
-Cl I ~ S ~ S 1~ ~ ~1 1 ~ ~ S O ~ ~ ~
cc I a~ ~ c ~ s o ~, c c.,_) ~ o o o
o~ o E u) E v~ ol u~ u) E'O c c
~QJ ~ /15 a~1~ E C ~u ~ a t~s o
EE I ~ X ~:~ E I ~:
I ~ a~ v~